Bristol-Myers Squibb Overview
Share Price
$59.72
(As of Friday Closing)
Bristol-Myers Squibb General Information
Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Bristol-Myers Squibb Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Bristol-Myers Squibb Stock Performance
(As of Tuesday closing)
| Stock Price |
Previous Close |
52 wk Range |
Market Cap |
Shares |
Average Volume |
EPS |
| $59.72 |
$59.81 |
$42.48 - $68.34 |
$135B |
2.26B |
17.7M |
$0.82 |
Bristol-Myers Squibb Financials Summary
In Thousands,
USD
|
TTM
31-Mar-2020
|
FY 2019
31-Dec-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
| EV |
158,354,707 |
143,062,835 |
85,428,692 |
101,748,957 |
| Revenue |
31,006,000 |
26,145,000 |
22,561,000 |
20,776,000 |
| EBITDA |
7,718,000 |
7,377,000 |
6,788,000 |
6,116,000 |
| Net Income |
954,000 |
3,439,000 |
4,920,000 |
1,007,000 |
| Total Assets |
129,285,000 |
129,944,000 |
34,986,000 |
33,551,000 |
| Total Debt |
47,530,000 |
47,538,000 |
7,349,000 |
7,962,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bristol-Myers Squibb Valuation & Funding
| Deal Type |
Date |
Amount |
Valuation/
EBITDA |
Post-Val |
Status |
Debt |
This information is available in the PitchBook Platform. To explore Bristol-Myers Squibb‘s full profile, request access.
Request a free trial
Bristol-Myers Squibb Competitors (53)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| Amgen |
Formerly PE-Backed |
Thousand Oaks, CA |
00000 |
00.000 |
000000000000 |
00.000 |
| 000 00000 |
Corporation |
Indianapolis, IN |
00000 |
|
000000 - 000 |
|
| 00000 & 00. |
Corporation |
Kenilworth, NJ |
00000 |
|
00000000 |
|
| 00000 000000000000 |
Formerly VC-backed |
South San Francisco, CA |
000 |
000.00 |
000000 - 000 |
000.00 |
| 000000 |
Formerly VC-backed |
Cambridge, MA |
0000 |
000.00 |
00000000000 |
000.00 |
Bristol-Myers Squibb Executive Team (49)
| Name |
Title |
Board Seat |
Contact Info |
| Giovanni Caforio MD |
Chief Executive Officer & Chairman |
|
|
| Nadim Ahmed |
Executive Vice President & President |
|
|
| Payal Roy |
President- Oncology / Immuno-Oncology |
|
|
| David Elkins |
Chief Financial Officer, Finance & Executive Vice President |
|
|
| Karen Santiago |
Chief Accounting Officer, Accounting & Controller, Finance |
|
|
22 Former Executives
Bristol-Myers Squibb Investors
| Investor Name |
Investor Type |
Holding |
Investor Since |
Participating Rounds |
Contact Info |
This information is available in the PitchBook Platform. To explore Bristol-Myers Squibb‘s full profile, request access.
Request a free trial
Bristol-Myers Squibb
Investments
&
Acquisitions (55)
To view Bristol-Myers Squibb‘s complete investment and acquisition history, request access >>
| Company Name |
Deal Date |
Deal Type |
Deal Size |
Industry |
Lead Partner |
| 000000 00000000000 |
27-May-2020 |
000000000 |
0000 |
Drug Discovery |
000000 000000 00.0 |
| 0000000000 |
26-May-2020 |
00000 00000 00 |
000.00 |
Drug Discovery |
|
| 0000000000 0000000 |
11-Mar-2020 |
00000 00000 00 |
000.00 |
Biotechnology |
|
| 0000000 |
20-Nov-2019 |
000000000000000000 |
000.00 |
Biotechnology |
00000000 0000000 00 |
| Vedanta Biosciences |
23-Sep-2019 |
Later Stage VC |
000.00 |
Biotechnology |
|
Bristol-Myers Squibb Subsidiaries (7)
| Company Name |
Industry |
Location |
Founded |
| IFM Therapeutics |
Drug Discovery |
Boston, MA |
2015 |
| 0000000 |
Drug Discovery |
Copenhagen North, Denmark |
0000 |
| 0000000 |
Biotechnology |
Summit, NJ |
0000 |
| 0000000-00000 0000 |
Foundation |
New York, NY |
0000 |
| 000000000000 |
Drug Discovery |
Seattle, WA |
0000 |
Bristol-Myers Squibb Exits (17)
| Company Name |
Exit Date |
Exit Type |
Exit Size |
Status |
Buyers |
| 000 000 |
19-Jul-2018 |
00000 00000 00 |
000.00 |
Completed |
|
| 00000 0000000000 ( |
21-Dec-2017 |
00000 00000 00 |
0000 |
Completed |
|
| 000000-0000000 000 |
22-Aug-2016 |
00 000000000000000 |
0000 |
Completed |
|
| 000000-0000000 000 |
01-Jan-2014 |
00000 0000000 |
|
Completed |
|
| CytomX Therapeutics |
31-Jul-2012 |
Early Stage VC |
0000 |
Completed |
|